Weight Loss

Novo Nordisk's Newly Approved Weight Loss Pill Shows Record Prescription Data
Novo Nordisk's Newly Approved Weight Loss Pill Shows Record Prescription Data
Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments
Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments
Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
FDA Says No Clear Link Found Between Popular Weight Loss Drugs And Suicidal Thoughts, Review Ongoing
FDA Says No Clear Link Found Between Popular Weight Loss Drugs And Suicidal Thoughts, Review Ongoing
Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight
Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight

Weight Loss Recent News

Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
Novo Nordisk launches Wegovy weight loss pill in the US, showing up to 17% weight loss, with prices starting near $5 a day and broad pharmacy and telehealth access.
Novo Nordisk Halves Wegovy Prices In China Ahead Of Generic Threat
Novo Nordisk Halves Wegovy Prices In China Ahead Of Generic Threat
Novo Nordisk has lowered prices for its obesity drug Wegovy by 50% in China, ahead of generic competition.
Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval
Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval
Food makers and restaurants adjust menus and products as GLP-1 drugs drive demand for high-protein foods and smaller portions across the U.S.
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback
When Mega-cap tech fades, pharma takes spotlight: LLY and NVO are top picks for long-term growth with strong demand for GLP-1 treatments.
Novo Nordisk Files FDA Application For Weekly Combination Obesity Shot
Novo Nordisk Files FDA Application For Weekly Combination Obesity Shot
Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.
After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss
After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss
Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in the U.S., U.K., and other markets.
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch
FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from May.
Eli Lilly's Next-Gen Experimental Drug Cuts Body Weight By 29%, Helps In Knee Pain
Eli Lilly's Next-Gen Experimental Drug Cuts Body Weight By 29%, Helps In Knee Pain
Lilly reports Phase 3 data showing retatrutide delivered substantial weight loss, reduced knee pain, and improved cardiovascular markers in adults with obesity and osteoarthritis.
Wave Life Sciences One-Shot Obesity Drug Slashes Dangerous Visceral Fat
Wave Life Sciences One-Shot Obesity Drug Slashes Dangerous Visceral Fat
Interim data from Wave Life Sciences' INLIGHT trial showed promising results for WVE-007, an investigational treatment for obesity.
Fractyl Health's Revita Procedure Helps Patients Keep Weight Off After Stopping GLP-1 Drugs
Fractyl Health's Revita Procedure Helps Patients Keep Weight Off After Stopping GLP-1 Drugs
Fractyl Health (NASDAQ: GUTS) released positive 6-month results from its REVEAL-1 study in obese patients who discontinued GLP-1 therapy.
Zepbound Just Got Cheaper: Lilly Cuts Prices On LillyDirect To Broaden Access
Zepbound Just Got Cheaper: Lilly Cuts Prices On LillyDirect To Broaden Access
Lilly drops Zepbound single-dose vial prices on LillyDirect, offering lower costs and more access options for patients with a valid prescription.
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy
Novo Nordisk files for FDA review of its higher-dose Wegovy after 72-week data show stronger weight loss than the current 2.4 mg option.
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients
Novo Nordisk's amycretin cut A1C and body weight in a phase 2 study, with no plateau seen, as the company targets a 2026 phase 3 launch.
Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients
Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients
Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026.
Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch
Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch
Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India to defend market share.
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment
Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved